NISN yields 294.12% · PFE yields 6.13%● Live data
📍 NISN pulled ahead of the other in Year 1
Combined, NISN + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NISN + PFE for your $10,000?
Nisun International Enterprise Development Group Co., Ltd, an investment holding company, provides technology-driven integrated supply chain solutions for enterprises and financial institutions in the People's Republic of China and internationally. It offers professional solutions for technology supply chain management, technology asset routing, and digital transformation of tech and finance institutions. The company also provides a range of technology-driven customized financing solutions to small- and mid-sized enterprises (SMEs) to enhance SMEs' access to capital through its closed-loop ecosystem built on fintech platforms; and direct banking solutions to small- and medium-sized commercial banks and other financial institutions in their distribution and management of direct banking and other financial products. Nisun International Enterprise Development Group Co., Ltd has a strategic collaboration with Henan Wanbang International Agricultural Products Logistics Co., Ltd. for cooperation on businesses related to the agricultural field. The company was formerly known as Hebron Technology Co., Ltd. and changed its name to Nisun International Enterprise Development Group Co., Ltd in September 2020. Nisun International Enterprise Development Group Co., Ltd was founded in 2005 and is headquartered in Shanghai, the People's Republic of China.
Full NISN Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.